Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1407 - Incidence of permanent chemotherapy-induced alopecia among breast cancer patients: A five-year prospective cohort study (80P)


18 Nov 2017


Poster lunch


Supportive Care and Symptom Management;  Therapy;  Breast Cancer


Danbee Kang


Annals of Oncology (2017) 28 (suppl_10): x16-x24. 10.1093/annonc/mdx655


D. Kang1, I. Kim2, D. Lee3, J.S. Ahn4, J. Park3, E. Guallar5, J. Cho1

Author affiliations

  • 1 Department Of Clinical Research Design And Evaluation, Saihst, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 2 Cancer Education Center, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 3 Department Of Dermatology, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 4 Division Of Hematology/oncology, Department Of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 5 Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA, Baltimore/US


Abstract 1407


While chemotherapy-induced alopecia is considered temporary and usually reversible within 1-6 months after chemotherapy, some patients report persistent alopecia several years after chemotherapy. The frequency of long-term permanent chemotherapy-induced alopecia (PCIA) and hair related changes is unknown. This study aimed to assess the incidence of PCIA among breast cancer patients by quantifying changes in hair density and thickness before chemotherapy, after two cycles of chemotherapy, and one, three, six, and 36 months after completion of chemotherapy.


This was a prospective cohort study of 61 patients 18 years of age or older with a postoperative diagnosis of stage I to III breast cancer who received adjuvant chemotherapy between February and September 2012 at an outpatient breast cancer clinic in Korea. Objective hair density and thickness were measured using a noninvasive bioengineering device.


At 6 months after completion of chemotherapy, 11.5% and 30.8% of patients experienced PCIA in terms of hair density and thickness, which did not recover until after 36 months after completion of chemotherapy. Patients who received a combination of doxorubicin and cyclophosphamide followed by four additional cycles of paclitaxel were more likely to experience PCIA compared to patients with other type of chemotherapy. Patients who had PCIA were more likely to have significantly lower body image compared to patients without PCIA.


Permanent and severe alopecia is a common side effect of breast cancer adjuvant chemotherapy. Additional research is necessary to translate these findings into interventions for improving distress due to permanent alopecia in breast cancer patients after completion of chemotherapy.

Clinical trial identification

Legal entity responsible for the study

Samsung Medical Center


This research was supported by Basic Science Research Program through the National Research Foundation of Korea(NRF) funded by the Ministry of Education (grant number: 2017R1D1A1B03031654).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.